Plain English Summary
This bill requires pharmaceutical manufacturers to include specific information in advertisements for prescription drugs and biological products shown to North Carolina consumers. The required disclosures include the FDA approval date, the date the drug became available for purchase, and detailed information about clinical trials related to any required side effect warnings, such as trial length, number of participants, and frequency of side effects.
Arguments in Favor
Supporters argue this bill helps consumers make informed decisions by providing concrete data about drug safety and efficacy directly in advertisements. They contend that current ads mention side effects but lack the specific trial details needed to understand how common or serious those risks truly are, and that transparency about approval timelines helps consumers assess how long a drug has been on the market.
Arguments Against
Opponents may argue this requirement creates burdensome compliance costs for manufacturers and could make advertisements cluttered or difficult to present within time or space constraints in media like television or radio. They might also contend that federal FDA regulations already require adequate safety disclosures and that additional state-level requirements could complicate advertising across multiple states or duplicate existing protections.
AI-generated analysis based on bill text. Always verify with official sources at ncleg.gov. This is not legal or political advice.
Sponsors
Primary Sponsor
Representative · District 76
Primary Sponsor
Representative · District 109
Primary Sponsor
Representative · District 83
Cosponsors (9)
Representative · District 5
Representative · District 84
Representative · District 114
Representative · District 53
Representative · District 61
Representative · District 52
Representative · District 79
Representative · District 73
Representative · District 101